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BACKGROUND
Health care access is an important determinant of health. We assessed 
the effect of health insurance status and type on blood pressure control 
among US women living with (WLWH) and without HIV.
METHODS
We used longitudinal cohort data from the Women’s Interagency HIV Study 
(WIHS). WIHS participants were included at their first study visit since 2001 
with incident uncontrolled blood pressure (BP) (i.e., BP ≥140/90 and at 
which BP at the prior visit was controlled (i.e., <135/85). We assessed time 
to regained BP control using inverse Kaplan–Meier curves and Cox pro-
portional hazard models. Confounding and selection bias were accounted 
for using inverse probability-of-exposure-and-censoring weights.
RESULTS
Most of the 1,130 WLWH and 422 HIV-uninfected WIHS participants 
who had an elevated systolic or diastolic measurement were insured via 
Medicaid, were African-American, and had a yearly income ≤$12,000. 
Among participants living with HIV, comparing the uninsured to those 
with Medicaid yielded an 18-month BP control risk difference of 0.16 (95% 
CI: 0.10, 0.23). This translates into a number-needed-to-treat (or insure) 
of 6; to reduce the caseload of WLWH with uncontrolled BP by one case, 
five individuals without insurance would need to be insured via Medicaid. 
Blood pressure control was similar among WLWH with private insurance 
and Medicaid. There were no differences observed by health insurance sta-
tus on 18-month risk of BP control among the HIV-uninfected participants.
CONCLUSIONS
These results underscore the importance of health insurance for hyper-
tension control—especially for people living with HIV.
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Control of Hypertension and Insurance
Health care availability and quality are important deter-
minants of health.1 About 15% of the United States (US) 
population lacked health insurance prior to the Affordable 
Care Act; Blacks and Hispanics, racial/ethnic groups that 
are disproportionately both poor and affected by HIV 
and hypertension, were more likely to be uninsured.2 The 
positive effect of health insurance on blood pressure con-
trol has been documented in the general population. For 
example, an analysis of the National Health and Nutrition 
Examination Survey from 1999 to 2002 showed that among 
participants with hypertension, the uninsured were less 
likely than the insured to have had recent blood pressure 
monitoring, to be taking antihypertensive medications, 
and to have adequately controlled blood pressure.3 In the 
Women’s Health Initiative, women on Medicaid were given 
medication to treat hypertension at a rate of 81%—higher 
than treatment rates among women with private insurance 
(63–65%) or Medicare only (64%).4 In this same study, par-
ticipants seeing a health care provider in the past year were 
four times as likely to be on medication to control hyper-
tension as those who had not seen a provider. These posi-
tive effects of health insurance on blood pressure control 
are likely due to a combination of reduction in cost barri-
ers to seeking healthcare, increased screening for hyper-
tension, appropriate lifestyle counseling, and prescription 
coverage of antihypertensive drugs.
Some individuals living with HIV may also have cover-
age of antihypertensive medications through the AIDS 
Drug Assistance Program (ADAP), a federal program that 
provides HIV-related prescription drugs to low-income 
individuals with limited or no prescription drug coverage. 
Individual states set the requirements for ADAP eligibility 
and drug formularies, and non-HIV medication coverage. 
For example, in 2015, New York and Illinois covered anti-
hypertensive medications, but California did not.5 There has 
been limited research about the effects of ADAP on hyper-
tension control. In one study among WIHS WLWH diag-
nosed with hypertension, women enrolled in ADAP showed 
a nonsignificant trend toward increased use of antihyperten-
sive medications.6
While there have been studies on predictors of incident 
or prevalent hypertension among WLWH, to our knowledge 
there have been no prospective studies of health insurance 
type on blood pressure control among individuals living 
with HIV.
METHODS
Women’s Interagency HIV Study. Recruitment, retention, 
and study characteristics of WIHS participants have been 
previously reported.7,8 In brief, WLWH and HIV-uninfected 
women were recruited to participate in WIHS during four 
waves, during calendar years 1994–1995, 2001–2002, 2011–
2012, and 2013–2015. This report includes women recruited 
during the first three waves. This included participants from 
Brooklyn, Bronx, Chicago, Washington DC, Los Angeles, 
and San Francisco. Study visits are conducted approximately 
every six months and consist of a structured interview, clini-
cal examination, and specimen collection. To assess time 
to controlled blood pressure, we included participant-time 
starting at incident high blood pressure. Participants were 
included in this report at the first study visit since 2001 at 
which their systolic blood pressure (BP) was ≥140 or dias-
tolic BP was ≥90 (henceforth the index visit), following a 
visit in which BP was controlled (i.e., systolic < 135 and dias-
tolic < 85).
This study was approved by the University of North 
Carolina Institutional Review Board; data collection proce-
dures are supervised by the Institutional Review Boards at 
each participating WIHS institution.
Ascertainment of BP. Blood pressure measurements are 
taken using a standardized protocol: BP is measured after 
sitting for at least 5 minutes and at least 30 minutes after 
the intake of nicotine or caffeine. A  second BP reading is 
taken after 1 minute, after elevation of the arm over the head 
for 5 seconds between readings; the two readings are then 
averaged to generate the blood pressure that is used in these 
analyses. Blood pressure was considered controlled if the 
systolic BP was <135 and the diastolic BP was <85.
Ascertainment of health insurance status, and 
covariates. Insurance type was the primary exposure of 
interest, and was allowed to vary with time. Participants 
self-reported their insurance coverage at each study visit. 
Using a classification hierarchy similar to the one described 
in the Kaiser Issue Brief,9 we categorized insurance into 
four mutually exclusive categories. Insurance categories 
were assigned in this order: Medicaid or Medi-Cal, private 
insurance (including student health insurance), Medicare 
and other public insurance (including Tricare/CHAMPUS, 
Veteran’s Administration, and city or county coverage), 
and no health insurance. The text fields for those who 
reported other types of insurance were manually catego-
rized into these groups as appropriate. There were only 
52 participants who were categorized into the Medicare/
other public insurance category, so we omitted those visits 
from analyses. Participants living with HIV also reported 
participation in ADAP, which may have been available to 
participants in any insurance category depending on state 
of residence and income.
Birthdate, race/ethnicity (categorized in this study as 
Hispanic, African American (non-Hispanic), White (non-
Hispanic), or other), recruitment wave, and educational 
attainment (in categories of less than, equal to, or more 
than high school education) were collected at entry into the 
WIHS cohort. Body mass index (BMI) is calculated from 
measurements at each visit; CD4+ T lymphocyte counts and 
HIV-1 RNA levels (viral load) were measured at each visit 
for participants living with HIV. Annual household income 
and drug use in the past 6 months are self-reported at each 
visit. Participants were asked if they had seen a healthcare 
provider, and how often they had seen a healthcare provider 
over the past 6  months at study visits through September 
2008, at which point the question was dropped from the 
questionnaire.
Statistical methods. We counted person-time from 
elevated BP to the earliest of: blood pressure control 
(i.e., <135/85), drop-out (i.e., 1  year of missed visits), or 
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4  years (i.e., administrative censoring). The complement 
of the Kaplan–Meier survival curve estimator10 was used 
to estimate the cumulative risk of BP control. Risk differ-
ences were estimated by the difference in Kaplan–Meier 
estimates between the groups. Variance of the risk differ-
ence was calculated by summing the Greenwood variance 
estimates from both groups. The number of persons who 
would require insurance to reduce the uncontrolled blood 
pressure caseload by one case, or number needed to treat 
(NNT), was calculated as the reciprocal of the estimated 
risk difference.
Observed data were weighted by the product of stabilized 
inverse probability-of-exposure-and-censoring weights to 
account for confounding and selection bias by measured 
characteristics.11,12 Given a well-defined exposure or treat-
ment, conditional exchangeability (i.e., no unmeasured 
confounding), and positivity (i.e., individuals in each strata 
defined by the exposure and covariates), and correct model 
specification our results provide a consistent estimate of the 
difference between risk functions.13 Health insurance type 
was modeled using pooled multinomial regression; censor-
ing was modeled using pooled logistic regression. Models 
were fit for participants living with and without HIV infec-
tion separately.
For participants living with HIV confounders included age 
(using restricted quadratic splines (RQS) with knots at 40, 45, 
49, and 53 years14), race/ethnicity (categorized as Hispanic, 
Black (non-Hispanic) and White (non-Hispanic), and other), 
study site, CD4+ cell count (lagged 6 months, using RQS with 
knots at 234, 362, 515, 705 cells/μl), HIV viral load (lagged 
6  months, log transformed, using RQS with knots at 1.90, 
1.90, 2.89, 4.17 log(copies/ml)), BMI (lagged 6  months, 
using RQS with knots at 23.2, 26.3, 30.1, 35.7  kg/m2), and 
previous health insurance status (lagged 6 and 12 months). 
Not included as confounders in the final weight model were 
illicit drug use and the Center for Epidemiologic Studies 
Depression Scale (CES-D) as these variables did not alter the 
variance or final effect estimate. The resultant weights had a 
mean (SD) of 1.00 (0.53) and range of 0.03–14.87.
For HIV-uninfected participants confounders included 
age (using RQS with knots at 36, 42, 47, and 52 years14), race/
ethnicity (categorized as Hispanic, Black (non-Hispanic) and 
White (non-Hispanic), and other), study site, BMI (lagged 
6 months, using RQS with knots at 25.7, 29.1, 33.4, 39.6 kg/
m2) and history of health insurance status (lagged 6 and 
12 months). Not included as confounders in the final weight 
model were drug use and CES-D as these variables did not 
alter the variance or final effect estimate. The resultant weights 
had a mean (SD) of 1.00 (0.62) and ranged from 0.05 to 9.00.
Cox proportional hazards models were fit using PROC 
PHREG with a weight statement to incorporate the inverse 
probability of treatment and censoring weights. All analyses 
were conducted using SAS 9.3 (SAS Institute, Cary, NC).
RESULTS
Demographic characteristics of the WIHS participants, 
1,130 living with HIV and 415 HIV-uninfected, who had 
an elevated systolic or diastolic measurement are shown 
in Tables 1 and 2.  A  substantial proportion of all partici-
pants had Medicaid as their insurer (WLWH 68%, HIV-
uninfected participants 57%); however, the proportion of 
uninsured participants was higher among HIV-uninfected 
women (n  =  101, 24%) than WLWH (n  =  127, 11%). The 
WIHS participants are low-income, and that is reflected in 
the high proportion (58% among WLWH and 53% among 
HIV-uninfected participants) who report yearly income 
below $12,000/year.
Due to questionnaire changes, not all participants were 
asked about healthcare visits. Among the participants who 
were asked, 71% of women living without HIV infection 
(213/299) and 92% of women living with HIV infection 
(793/866) reported they had seen a healthcare provider in 
the past 6 months. The mean number of visits among those 
who had any healthcare visit was 4.3 among HIV-uninfected 
women and 5.1 among WLWH.
Among WLWH, uninsured participants were younger, 
had higher HIV viral load, were more likely to be Hispanic, 
and were more likely to be enrolled in ADAP. Given the small 
proportion of participants who were enrolled in ADAP in 
each insurance group (e.g., only 7.4% of Medicaid partici-
pants had ADAP), we were unable to stratify by ADAP par-
ticipation. Privately insured participants had higher incomes 
and those who were uninsured or on Medicaid reported 
lower incomes. There were few other demographic differ-
ences between insurance groups among HIV-uninfected 
participants.
Crude and weighted curves of time to blood pressure con-
trol are presented in Figures 1 and 2. After accounting for 
age, CD4 cell count, race/ethnicity, BMI, HIV viral load, and 
study site, uninsured WLWH were the least likely to achieve 
a subsequent BP under 135/85 compared to both groups of 
insured WLWH. While all covariates contributed to adjusted 
estimates, weighting for age, a known predictor of both 
health insurance and blood pressure elevation, contributed 
the most to separating the uninsured group from the others. 
Among the HIV-uninfected participants after accounting 
for age, race/ethnicity, BMI, and study site, health insurance 
did not affect the proportion of participants who had a sub-
sequent BP under 135/85.
In Table  3, we report the weighted cumulative risk of 
blood pressure control by 18  months after blood pressure 
elevation. As study visits are not clinical encounters for 
WIHS study participants, we chose 18 months as a reason-
able amount of time for a participant to seek medical care in 
response to elevated blood pressure. The differences among 
the HIV-uninfected participants were minimal. However, 
among WLWH, comparing the uninsured to those with 
Medicaid yielded a risk difference of 0.16 (95% CI: 0.10, 
0.23). This risk difference translates into a number needed to 
treat (i.e., insure) of 6. This means that to reduce the overall 
caseload of patients with uncontrolled blood pressure by one 
case, six uninsured participants would need to be insured via 
Medicaid.
We conducted two sensitivity analyses modifying the 
required high blood pressure measurement at entry: systolic 
BP ≥150 or diastolic BP ≥90, and two visits of systolic BP 
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≥140 or diastolic BP ≥90. Both of these sensitivity analyses 
did not substantially change the results (data not shown).
DISCUSSION
We examined in a predominantly low-income group 
the relationship between health insurance and control of 
hypertension among women living with HIV and a women 
with risk factors for HIV infection. We found that among 
WLWH, being uninsured was associated with less control of 
hypertension compared with women who were on Medicaid 
or were privately insured.
Among HIV-uninfected women, insurance did not convey 
the same benefits. This may be due to fewer health care visits 
among the HIV-uninfected women. Compared to WLWH, 
21% fewer HIV-uninfected women saw a healthcare provider 
in the 6 months prior to their baseline visit. Even among those 
who visited a healthcare provider, HIV-uninfected women 
had a lower frequency of health care visits than the WLWH. 
Additionally, the number of HIV-uninfected individuals in 
each health insurance category was small, limiting the infer-
ence that can be drawn with precision.
Lower blood pressure control among uninsured WLWH in 
our study is consistent with results from the general population: 
Table 1. Demographic characteristics of HIV-infected participants at first observed blood pressure elevation
No insurance 
(n = 127) Medicaid (n = 772) Private (n = 179) Total (n = 1,130)
N % N % N % N %
On ADAP 60 47.2 57 7.4 44 24.6 178 15.8
No ART 48 37.8 224 29.0 43 24.0 328 29.0
Race/ethnicity
 African-American 78 61.4 529 68.5 94 52.5 726 64.2
 White 8 6.3 64 8.3 52 29.1 134 11.9
 Hispanic 38 29.9 159 20.6 23 12.8 236 20.9
 Other 3 2.4 20 2.6 10 5.6 34 3.0
≥HS education 67 52.8 440 57.0 160 89.4 706 62.5
Income
 $0–$12,000 79 62.2 522 67.6 25 14.0 658 58.2
 $12,001–$30,000 35 27.6 198 25.6 41 22.9 291 25.8
 ≥$30,001 13 10.2 52 6.7 113 63.1 181 16.0
Site
 Bronx 5 3.9 192 24.9 13 7.3 214 18.9
 Brooklyn 23 18.1 137 17.7 32 17.9 194 17.2
 Washington, DC 20 15.7 88 11.4 49 27.4 170 15.0
 LA 38 29.9 86 11.1 29 16.2 169 15.0
 San Francisco 11 8.7 154 19.9 26 14.5 201 17.8
 Chicago 30 23.6 115 14.9 30 16.8 182 16.1
HDL ≤ 40 mg/dl 46 36.2 221 28.6 169 94.4 310 27.4
LDL ≥ 130 mg/dl 24 18.9 134 17.4 50 27.9 208 18.4
Median (IQR) Median (IQR) Median (IQR) Median (IQR)
Age 42 (37,47) 46 (41, 51) 45 (39, 52) 46 (40, 51)
CD4 cell count 463 (294, 599) 430 (251, 650) 523 (336, 709) 445 (274, 655)
HIV viral load 570 (80, 19,000) 174 (80, 9,450) 80 (80, 1,900) 132 (80, 7,318)
BMI 29.4 (24.5, 36.5) 28.5 (24.2, 34.2) 27.8 (23.9, 33.0) 28.3 (24.2, 34.0)
Systolic BP at BS 142 (135, 148) 142 (136, 149) 141 (134, 147) 142 (136, 149)
Diastolic BP at BS 90 (82, 92) 90 (84, 93) 90 (80, 92) 90 (83, 92)
Waist circumference (cm) 97.0 (84.5, 108.4) 96.1 (83.2, 107.2) 94.8 (82.6, 103.4) 96.0 (83.2, 106.4)
BP elevation (≥140/90), when the BP at the prior visit was controlled (i.e., systolic <135 and diastolic <85).
Abbreviations: ADAP, AIDS Drug Assistance Program; ART, antiretroviral therapy; BMI, body mass index; BP, blood pressure; BS, baseline; 
HDL, high density lipoprotein; HS, high school; IQR, interquartile range; LA, Los Angeles; LDL, low density lipoprotein.
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uninsured individuals are least likely to have controlled blood 
pressure.3 Prior work in the WIHS cohort has shown that 
hypertension prevalence is similar between participants liv-
ing with and without HIV.15 The authors identified increas-
ing age, African-American race, BMI >30 kg/m as associated 
with increasing prevalence of hypertension, and pregnancy as 
protective. In an international, longitudinal HIV cohort, male 
sex, higher BMI, older age, higher BP at baseline, high total 
cholesterol and clinical lipodystrophy, and not antiretroviral 
drug class, have been associated with incident hypertension.16 
However, our work suggests further research is needed to com-
pare the amount of time individuals spend with uncontrolled 
hypertension—future studies may find that the increased con-
tact with healthcare providers insured individuals living with 
HIV have leads to improved blood pressure control.
Guidelines about treatment of hypertension are in flux. 
This is due in part to the SPRINT trial, which showed a 
benefit among those at high cardiovascular risk to targeting 
blood pressure reduction strategies to <120/80 rather than 
the previously recommended target of <140/90.17 There is 
continuing discussion about best practices for individuals 
who are not at high cardiovascular risk. However, regardless 
of the health and longevity benefits to blood pressure control 
seen in randomized trials, access to health care and prescrip-
tion medications remains a barrier to better blood pressure 
control on a population level.
There are some limitations to this report. First, par-
ticipants may not have correctly self-reported their health 
insurance leading to potential exposure misclassification. 
However, studies have shown18–20 that those who self-
reported no insurance are likely uninsured, supporting our 
conclusions about the WLWH who were uninsured. Second, 
as in all observational studies, we rely on the assumption 
of no unmeasured confounding. Given the difficulty of 
Table 2. Demographic characteristics of HIV-uninfected participants at first observed blood pressure elevation
No insurance 
(n = 101) Medicaid (n = 236) Private (n = 78) Total (n = 415)
N % N % N % N %
Race/ethnicity
 African-American 70 69.3 158 66.9 57 73.1 285 68.7
 White 5 5.0 16 6.8 9 11.5 30 7.2
 Hispanic 24 23.8 51 21.6 10 12.8 85 20.5
 Other 2 2.0 11 4.7 2 2.6 15 3.6
≥HS education 61 60.4 140 59.3 68 87.2 269 64.8
Income
 $0–$12,000 62 61.4 147 62.3 10 12.8 219 52.8
 $12,001–$30,000 27 26.7 77 32.6 27 34.6 131 31.6
 ≥$30,001 12 11.9 12 5.1 41 52.6 65 15.7
Site
 Bronx 14 13.9 85 36.0 18 23.1 117 28.2
 Brooklyn 16 15.8 28 11.9 19 24.4 63 15.2
 Washington, DC 12 11.9 25 10.6 16 20.5 53 12.8
 LA 28 27.7 25 10.6 5 6.4 58 14.0
 San Francisco 18 17.8 44 18.6 8 10.3 70 16.9
 Chicago 13 12.9 29 12.3 12 15.4 54 13.0
HDL ≤ 40 mg/dl 13 12.9 35 14.8 17 21.8 65 15.7
LDL ≥ 130 mg/dl 24 23.8 45 19.1 18 23.1 87 21.0
Median (IQR) Median (IQR) Median (IQR) Median (IQR)
Age 45 (37, 50) 44 (37, 51) 45 (37, 49) 44 (37, 50)
BMI 27.9 (23.5, 33.4) 31.7 (27.5, 38.8) 33.9 (28.3, 39.2) 31 (26, 38)
Systolic BP at BS 143 (140, 150) 142 (140, 150) 141 (140, 147) 142 (136, 149)
Diastolic BP at BS 90 (83, 95) 89 (81, 93) 88 (81, 91) 90 (83, 92)
Waist circumference (cm) 95.0 (80.3, 106.6) 101.5 (87.4, 112.1) 104.5 (94, 113.9) 100.5 (86.6, 111.5)
BP elevation (≥140/90), when the BP at the prior visit was controlled (i.e., systolic <135 and diastolic <85).
Abbreviations: BMI, body mass index; BP, blood pressure; BS, baseline; HDL, high density lipoprotein; HS, high school; IQR, interquartile 
range; LA, Los Angeles; LDL, low density lipoprotein.
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Figure 1. Time to control of blood pressure, after an elevated BP by health insurance status among women living with (left panel) and without (right 
panel) HIV.
Figure 2. Weighted time to control of blood pressure, after an elevated BP by health insurance status among women living with (left panel, account-
ing for age, CD4 cell count, race/ethnicity, BMI, HIV viral load, and study site) and without (right panel, accounting for age, race/ethnicity, BMI, and 
study site) HIV.
Table 3. Weighted cumulative risk of blood pressure control 18 months after elevation by health insurance status
Risk 95% CI Risk difference 95% CI NNT
HIV-infected participants
 Uninsured 0.33 0.27, 0.39 0.16 0.10, 0.23 6
 Medicaid 0.49 0.46, 0.52 0
 Private Insurance 0.43 0.37, 0.49 0.06 0.00, 0.12 17
HIV-uninfected participants
 Uninsured 0.33 0.25, 0.39 0.02 −0.06, 0.11 44
 Medicaid 0.35 0.30, 0.39 0
 Private Insurance 0.33 0.25, 0.41 0.02 −0.08, 0.11 60
Abbreviations: CI, confidence interval; NNT, number needed to treat (i.e., insure).
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randomizing an exposure like health insurance, this analy-
sis provides important information about the likely effects 
of health insurance on blood pressure using modern ana-
lytic methods. Third, the observation of an elevated BP at a 
WIHS visit is not necessarily associated with clinical follow 
up. Assuming that clinical follow up does result in lifestyle 
changes or prescription of anti-hypertension medication, 
the results from this analysis would underestimate the effect 
of insurance on hypertension control. Fourth, participants 
in the WIHS, a long-term cohort study, may differ from the 
population living with HIV in the United States, limiting 
generalizability. In comparison with clinic-based cohorts, 
however, the WIHS has the substantial advantage of includ-
ing participants who are not linked to care.
There are a number of strengths to this study. WIHS 
data enables a longitudinal study design with a large study 
population. The retention for this cohort is high, and conse-
quently there is minimal missing data. The data are managed 
by a central data processing center that checks for internal 
consistency and data quality. In addition, we used an ana-
lytic strategy that appropriately controls for time-varying 
confounding.
In conclusion, these results highlight the importance of 
health insurance for hypertension control.
Future directions
There have been a number of changes in the health 
care system resulting from the Affordable Care Act that 
have increased the number of insured individuals in the 
United States, including expansion of eligibility criteria for 
Medicaid. However, not all states have expanded Medicaid 
coverage, leaving a gap in health care access for the working 
poor.21 In addition, the future of the Affordable Care Act is 
uncertain. For the population living with HIV, our results 
suggest that the current coverage gap represents a missed 
opportunity for improving blood pressure control.
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